Boston Scientific Drug-Eluting Stent Program: Setting a High Standard

The TAXUS™ paclitaxel-eluting coronary stent system is a revolutionary new treatment for coronary artery disease. Several years of consistent results across a number of clinical trials have demonstrated that our polymer-based delivery of paclitaxel is a safe and effective therapy for a broad spectrum of patients, including those with complex lesions. Among other things, the data have reported very low restenosis rates and significant improvements for diabetic patients. In particular, the data have reported a lack of edge effect outside the stent, which is a distinguishing feature of our program.

Another important feature of the TAXUS product is its platform – the Express^2™ coronary stent system, which offers excellent deliverability to the treatment site and outstanding conformability to the vessel wall. For the TAXUS product, the paclitaxel drug, our Translute™ polymer, our clinical trials, and the Express² stent system are helping to set a very high standard in the area of drug-eluting stents.